Thursday, July 31, 2008
House Votes to Let FDA Regulate Tobacco - NYTimes.com
House Votes to Let FDA Regulate Tobacco - NYTimes.com: "Decades after the surgeon general first warned that cigarettes were a health hazard, the House of Representatives overwhelmingly approved legislation on Wednesday that would for the first time give the Food and Drug Administration the power to regulate tobacco products."/.../
Diretrizes Brasileiras sobre Diagnóstico, Tratamento e Prevenção da Febre Reumática
SBC lidera discussão sobre diretrizes de febre reumática
Nesta sexta-feira e sábado, dias 1º e 2 de agosto, a Sociedade Brasileira de Cardiologia (SBC) lidera reunião que discutirá a elaboração das Diretrizes Brasileiras sobre Diagnóstico, Tratamento e Prevenção da Febre Reumática. O encontro, realizado com o apoio da Secretaria de Saúde do Estado da Bahia, acontecerá em Salvador com a presença do presidente da Câmara dos Deputados, Arlindo Chinaglia, representando o governo federal, dos secretários de Saúde da Bahia e de Salvador e, também, das sociedades de Pediatria e de Reumatologia.
O evento é da maior relevância, na avaliação do vice-presidente da SBC, Paulo José Bastos Barbosa. “A diretriz servirá de pilar básico para posterior construção de um programa de prevenção e controle da febre reumática no país”, declara. Segundo ele, a exemplo do que foi realizado na Austrália e na Índia, por exemplo, no documento constarão recomendações baseadas na realidade nacional particularmente do sus.
Diretrizes Brasileiras sobre Diagnóstico, Tratamento e Prevenção da Febre Reumática
Nesta sexta-feira e sábado, dias 1º e 2 de agosto, a Sociedade Brasileira de Cardiologia (SBC) lidera reunião que discutirá a elaboração das Diretrizes Brasileiras sobre Diagnóstico, Tratamento e Prevenção da Febre Reumática. O encontro, realizado com o apoio da Secretaria de Saúde do Estado da Bahia, acontecerá em Salvador com a presença do presidente da Câmara dos Deputados, Arlindo Chinaglia, representando o governo federal, dos secretários de Saúde da Bahia e de Salvador e, também, das sociedades de Pediatria e de Reumatologia.
O evento é da maior relevância, na avaliação do vice-presidente da SBC, Paulo José Bastos Barbosa. “A diretriz servirá de pilar básico para posterior construção de um programa de prevenção e controle da febre reumática no país”, declara. Segundo ele, a exemplo do que foi realizado na Austrália e na Índia, por exemplo, no documento constarão recomendações baseadas na realidade nacional particularmente do sus.
Diretrizes Brasileiras sobre Diagnóstico, Tratamento e Prevenção da Febre Reumática
GEECAB em CURITIBA NO CONGRESSO da SBC
Auditório 12 (114)
Atividade Pré-Congresso do Grupo de Estudos sobre Epidemiologia
e Cardiologia baseada em Evidências – Geecabe e Ministério da Saúde
Horário das 14h - 18h
As Doenças Cardiovasculares (DCV), compondo o conjunto de Doenças Crônicas (também rotuladas como
Doenças e Agravos Não Transmissíveis – DANT), são mundialmente reconhecidas como responsáveis pelos mais altos índices de morbidade e mortalidade precoce, inclusive no Brasil. Essas doenças causam grande impacto econômico tanto pela demanda de assistência quanto pela repercussão sobre o trabalho e a produção, e têm também forte determinação social e maior expressão em populações menos favorecidas. Além do desafio aos especialistas na assistência aos seus casos clínicos, constituem-se num enorme problema de Saúde Pública somente redutível através de ações preventivas e de promoção da saúde coletiva.
Dirigentes da SBC e do MS já desenvolvem profícuo diálogo, resultando em programas de tratamento e ações de controle. Entretanto ainda há muito que mobilizar e fazer, motivo pelo qual o Grupo de Estudos sobre Epidemiologia e Cardiologia Baseada em Evidências (GEECAB) planejou um painel específico, junto à principal atividade científica da cardiologia nacional, visando aprofundar e estender a colaboração de cardiologistas e sanitaristas.
A desproporção entre a magnitude do problema e o tempo disponível para este primeiro painel, impõe limitações ao número de expositores e às suas apresentações. É desejável, entretanto, que a assistência de dirigentes e interessados de ambas as instituições seja a mais ampla possível, e que as discussões e elaboração de temas tenha continuidade, única forma de se encontrar novos caminhos e garantir os resultados almejados.
Atividades Pré-Congresso
06 de setembro, sábado
Objetivo: Oportunizar uma visão compartilhada (de especialistas e de saúde pública) sobre saúde cardiovascular da população brasileira, seus problemas e possíveis soluções.
Delineamento: Painel/Oficina em dois blocos, composto por membros da SBC e do MS e possíveis observadores da Federação Mundial de Cardiologia (WHF) e Organização Pan-Americana da Saúde (OPAS) e mídia, aberto para assistência e questionamento de congressistas.
Itens: motivação, visões de ambas as partes, determinação social de saúde/doença, recursos existentes, possíveis linhas de investigação e intervenção, esboço de agenda mínima de colaboração.
Coordenação: Drs. Gláucia Morais (SBC), Rosa Maria Sampaio (MS) e Aloyzio Achutti (SBC).
Programa
1o. Bloco (14h – 16h)
(em torno de 15 minutos no máximo para cada tópico/depoimento)
1.1-Motivação: breve apresentação de justificativa e motivação do encontro. (Dra. Gláucia Moraes, GEECAB)
(5 minutos)
1.2-Visão de cardiologista: problemas, prioridades e recursos (Dr. Antonio Carlos Palandri Chagas, Presidente da SBC, e Luiz Antônio de Almeida Campos, Diretor Científico da SBC)
1.3-Visão de Saúde Pública: Doenças CV no contexto da Saúde Pública no Brasil e recursos do SUS (Dr. José Noronha, Secretário de Assistência à Saúde e Dra. Rosa Maria Sampaio, Diretora do HIPERDIA, do MS.)
1.4-Estimativa de custos globais das DCV no Brasil (Dr Aloyzio Achutti)
1.5-Determinantes Sociais de Saúde e Doença, e Saúde Cardiovascular no Brasil (Maria do Carmo Leal - da Comissão de Determinantes Sociais)
1.6-Política de medicamentos (Dr. Reinaldo Guimarães da Secretaria de Ciência e Tecnologia do MS e Dr. Dirceu Barbano, diretor do Departamento de Assistência Farmacêutica DAF do MS)
1.7-Política de Procedimentos de Alta Complexidade (Dr. Beltrame, Diretor do Departamento de Assistência Especializada DAE – MS) e (Rosemary da ANS).
2o. Bloco (16h15min – 18h)
2.1-O que a SBC espera do MS e proporia como linha de colaboração (Dr. Lázaro Fernandes de Miranda Diretor de Relações Governamentais da SBC).
2.2-Linhas prioritárias de investigação e de vigilância epidemiológica (Representantes das Secretarias de
Vigilância à Saúde - SVS e Coordenação de Vigilância de DANTS)
2.3-O que o MS espera da SBC e proporia como linha de colaboração (Participação ampliada, sob coordenação da Dra. Rosa Maria Sampaio).
2.4-Considerações dos observadores (WHF e OPAS)
2.5-Questionamentos e sugestões da assistência
2.6-Esboço de agenda mínima de colaboração objetiva, de curto e médio prazo (coordenação)
(Um esboço de documento será elaborado pela coordenação do evento, contando com contribuições, que serão bem vindas, incorporando-se posteriormente novas idéias, sugestões e recomendações levantadas durante a reunião)
Lista de Documentos básicos para informação e discussão:
http://departamentos.cardiol.br/geecabe/proposta-geecabe.asp
http://hiperdia.datasus.gov.br/
Nota final: os tópicos fundamentais do documento serão apresentados ao final para uma aprovação preliminar e serão colhidos endereços eletrônicos dos componentes da mesa e da assistência para facilitar a circulação do documento até chegar a uma versão mais representativa para a devida divulgação e aplicação em ambas as instituições.
Atividade Pré-Congresso do Grupo de Estudos sobre Epidemiologia
e Cardiologia baseada em Evidências – Geecabe e Ministério da Saúde
Horário das 14h - 18h
As Doenças Cardiovasculares (DCV), compondo o conjunto de Doenças Crônicas (também rotuladas como
Doenças e Agravos Não Transmissíveis – DANT), são mundialmente reconhecidas como responsáveis pelos mais altos índices de morbidade e mortalidade precoce, inclusive no Brasil. Essas doenças causam grande impacto econômico tanto pela demanda de assistência quanto pela repercussão sobre o trabalho e a produção, e têm também forte determinação social e maior expressão em populações menos favorecidas. Além do desafio aos especialistas na assistência aos seus casos clínicos, constituem-se num enorme problema de Saúde Pública somente redutível através de ações preventivas e de promoção da saúde coletiva.
Dirigentes da SBC e do MS já desenvolvem profícuo diálogo, resultando em programas de tratamento e ações de controle. Entretanto ainda há muito que mobilizar e fazer, motivo pelo qual o Grupo de Estudos sobre Epidemiologia e Cardiologia Baseada em Evidências (GEECAB) planejou um painel específico, junto à principal atividade científica da cardiologia nacional, visando aprofundar e estender a colaboração de cardiologistas e sanitaristas.
A desproporção entre a magnitude do problema e o tempo disponível para este primeiro painel, impõe limitações ao número de expositores e às suas apresentações. É desejável, entretanto, que a assistência de dirigentes e interessados de ambas as instituições seja a mais ampla possível, e que as discussões e elaboração de temas tenha continuidade, única forma de se encontrar novos caminhos e garantir os resultados almejados.
Atividades Pré-Congresso
06 de setembro, sábado
Objetivo: Oportunizar uma visão compartilhada (de especialistas e de saúde pública) sobre saúde cardiovascular da população brasileira, seus problemas e possíveis soluções.
Delineamento: Painel/Oficina em dois blocos, composto por membros da SBC e do MS e possíveis observadores da Federação Mundial de Cardiologia (WHF) e Organização Pan-Americana da Saúde (OPAS) e mídia, aberto para assistência e questionamento de congressistas.
Itens: motivação, visões de ambas as partes, determinação social de saúde/doença, recursos existentes, possíveis linhas de investigação e intervenção, esboço de agenda mínima de colaboração.
Coordenação: Drs. Gláucia Morais (SBC), Rosa Maria Sampaio (MS) e Aloyzio Achutti (SBC).
Programa
1o. Bloco (14h – 16h)
(em torno de 15 minutos no máximo para cada tópico/depoimento)
1.1-Motivação: breve apresentação de justificativa e motivação do encontro. (Dra. Gláucia Moraes, GEECAB)
(5 minutos)
1.2-Visão de cardiologista: problemas, prioridades e recursos (Dr. Antonio Carlos Palandri Chagas, Presidente da SBC, e Luiz Antônio de Almeida Campos, Diretor Científico da SBC)
1.3-Visão de Saúde Pública: Doenças CV no contexto da Saúde Pública no Brasil e recursos do SUS (Dr. José Noronha, Secretário de Assistência à Saúde e Dra. Rosa Maria Sampaio, Diretora do HIPERDIA, do MS.)
1.4-Estimativa de custos globais das DCV no Brasil (Dr Aloyzio Achutti)
1.5-Determinantes Sociais de Saúde e Doença, e Saúde Cardiovascular no Brasil (Maria do Carmo Leal - da Comissão de Determinantes Sociais)
1.6-Política de medicamentos (Dr. Reinaldo Guimarães da Secretaria de Ciência e Tecnologia do MS e Dr. Dirceu Barbano, diretor do Departamento de Assistência Farmacêutica DAF do MS)
1.7-Política de Procedimentos de Alta Complexidade (Dr. Beltrame, Diretor do Departamento de Assistência Especializada DAE – MS) e (Rosemary da ANS).
2o. Bloco (16h15min – 18h)
2.1-O que a SBC espera do MS e proporia como linha de colaboração (Dr. Lázaro Fernandes de Miranda Diretor de Relações Governamentais da SBC).
2.2-Linhas prioritárias de investigação e de vigilância epidemiológica (Representantes das Secretarias de
Vigilância à Saúde - SVS e Coordenação de Vigilância de DANTS)
2.3-O que o MS espera da SBC e proporia como linha de colaboração (Participação ampliada, sob coordenação da Dra. Rosa Maria Sampaio).
2.4-Considerações dos observadores (WHF e OPAS)
2.5-Questionamentos e sugestões da assistência
2.6-Esboço de agenda mínima de colaboração objetiva, de curto e médio prazo (coordenação)
(Um esboço de documento será elaborado pela coordenação do evento, contando com contribuições, que serão bem vindas, incorporando-se posteriormente novas idéias, sugestões e recomendações levantadas durante a reunião)
Lista de Documentos básicos para informação e discussão:
http://departamentos.cardiol.br/geecabe/proposta-geecabe.asp
http://hiperdia.datasus.gov.br/
Nota final: os tópicos fundamentais do documento serão apresentados ao final para uma aprovação preliminar e serão colhidos endereços eletrônicos dos componentes da mesa e da assistência para facilitar a circulação do documento até chegar a uma versão mais representativa para a devida divulgação e aplicação em ambas as instituições.
Wednesday, July 30, 2008
Tau-Targeted Therapy Slows Alzheimer's Progression for 19 Months
CHICAGO, July 29 -- An old drug for urinary-tract infections, methylene blue (Urolene Blue), may hold the key to a therapy that can slow the progress of Alzheimer's disease for as long as 19 months, researchers here reported. After 24 months of treatment with 60 mg three times a day of methylthioninum chloride (rember), patients with moderate Alzheimer's disease achieved a treatment effect that "was twice the effect seen with donepezil (Aricept)," said Claude Wischik, Ph.D., of the University of Aberdeen in Scotland. The drug called rember is a formulation of methylene blue made by TauRx Therapeutics, and Dr. Wischik is founder and chairman of TauRx Therapeutics. The drug attacks tau, which promotes tangles, as opposed to amyloid plaques./.../
Tuesday, July 29, 2008
The Impact of Prevention on Reducing the Burden of Cardiovascular Disease -- Kahn et al. 118 (5): 576 -- Circulation
The Impact of Prevention on Reducing the Burden of Cardiovascular Disease -- Kahn et al. 118 (5): 576 -- Circulation: "Objective— Cardiovascular disease (CVD) is prevalent and expensive. While many interventions are recommended to prevent CVD, the potential effects of a comprehensive set of prevention activities on CVD morbidity, mortality, and costs have never been evaluated. We therefore determined the effects of 11 nationally recommended prevention activities on CVD-related morbidity, mortality, and costs in the United States."/.../
Noninvasive Coronary Artery Imaging
Since the early 1960s, selective x-ray coronary angiography has provided the only means of visualizing the coronary arterial system in vivo. However, it has several disadvantages. First, the incidence, albeit relatively low, of so-called major adverse events (death, myocardial infarction, or stroke) during or within 24 hours of selective coronary angiography is reported to be 0.2% to 0.3%, and the incidence of so-called minor complications (most of which are related to problems with the peripheral vessels through which catheters are inserted) is roughly 1% to 2%.1–3 Second, x-ray coronary angiography is accompanied by a modest amount of discomfort, because the placement of catheters is invasive. Third, it is expensive: the required equipment is costly, and the performance of the procedure necessitates considerable time and skill of highly trained physicians and support personnel. Last, the information obtained via catheter-based coronary angiography pertains to the coronary arterial lumen alone. As a result, alternative methods of visualizing the coronary arterial system that would allow one to avoid these disadvantages are desirable.
mobile health (IT)
BELLAGIO, Italy -- The United Nations Foundation and Vodafone Group Foundation’s Technology Partnership (Technology Partnership) announced today the start of a conference session designed to harness the potential of mobile health (mHealth) to unlock access to health data and improve healthcare in the developing world. Co-facilitated by the Technology Partnership and the Telemedicine Society of India, the session is part of the Rockefeller Foundation conference “Making the eHealth Connection: Global Partners, Local Solutions.”
The “mHealth and Mobile Telemedicine” session is gathering 25 private sector and public health leaders to explore the challenges, opportunities and way forward in building mHealth systems that can improve the access, efficiency and quality of health services in the developing world. The overarching goal of the Rockefeller Foundation conference is to develop a roadmap and global partnerships that support the use of emerging digital technologies to improve public health.
The “mHealth and Mobile Telemedicine” session is gathering 25 private sector and public health leaders to explore the challenges, opportunities and way forward in building mHealth systems that can improve the access, efficiency and quality of health services in the developing world. The overarching goal of the Rockefeller Foundation conference is to develop a roadmap and global partnerships that support the use of emerging digital technologies to improve public health.
Population growth and climate change
Population growth and climate change
Universal access to family planning should be the priority
The world’s population now exceeds 6700 million, and humankind’s consumption of fossil fuels, fresh water, crops, fish, and forests exceeds supply.1 These facts are connected. The annual increase in population of about 79 million means that every week an extra 1.5 million people need food and somewhere to live. This amounts to a huge new city each week, somewhere, which destroys wildlife habitats and augments world fossil fuel consumption. Every person born adds to greenhouse gas emissions, and escaping poverty is impossible without these emissions increasing. Resourcing contraception therefore helps to combat climate change, although it is not a substitute for high emitters reducing their per capita emissions. In 1798 Malthus predicted that as the population increased exponentially, shortfalls in food supply would be unavoidable.2 A sevenfold increase in the population has led, 210 years later, to unprecedented food shortages, escalating prices, and riots. Until these events Borlaug’s "green revolution"3 had seemingly proved Malthus wrong. Yet fertilisers, pesticides, tractors, and transport are dependent on fossil fuels, which apart from being in short supply, exacerbate climate change.4 5 /.../
Universal access to family planning should be the priority
The world’s population now exceeds 6700 million, and humankind’s consumption of fossil fuels, fresh water, crops, fish, and forests exceeds supply.1 These facts are connected. The annual increase in population of about 79 million means that every week an extra 1.5 million people need food and somewhere to live. This amounts to a huge new city each week, somewhere, which destroys wildlife habitats and augments world fossil fuel consumption. Every person born adds to greenhouse gas emissions, and escaping poverty is impossible without these emissions increasing. Resourcing contraception therefore helps to combat climate change, although it is not a substitute for high emitters reducing their per capita emissions. In 1798 Malthus predicted that as the population increased exponentially, shortfalls in food supply would be unavoidable.2 A sevenfold increase in the population has led, 210 years later, to unprecedented food shortages, escalating prices, and riots. Until these events Borlaug’s "green revolution"3 had seemingly proved Malthus wrong. Yet fertilisers, pesticides, tractors, and transport are dependent on fossil fuels, which apart from being in short supply, exacerbate climate change.4 5 /.../
Alzheimer's Linked to Thyroid-Related Hormone
"BOSTON, July 28 -- Abnormal levels of the hormone thyrotropin, which controls thyroid function, may be associated with an increased risk of Alzheimer's disease in women, researchers found."
Guideline Update on Valvular Heart Disease: Focused Update on Infective Endocarditis.
ACC/AHA 2008 Guideline Update on Valvular Heart Disease: Focused Update on Infective Endocarditis. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines -- Nishimura et al., 10.1161/CIRCULATI
These updated guideline recommendations reflect a consensus of expert opinion after a thorough review primarily of late-breaking clinical trials identified through a broad-based vetting process as important to the relevant patient population, and of other new data deemed to have an impact on patient care (see Section 1.1 “Evidence Review” for details regarding this focused update). It is important to note that this
focused update is not intended to represent an update based on a full literature review from the date of the previous guideline publication. /.../
These updated guideline recommendations reflect a consensus of expert opinion after a thorough review primarily of late-breaking clinical trials identified through a broad-based vetting process as important to the relevant patient population, and of other new data deemed to have an impact on patient care (see Section 1.1 “Evidence Review” for details regarding this focused update). It is important to note that this
focused update is not intended to represent an update based on a full literature review from the date of the previous guideline publication. /.../
Sleep Apnea and Cardiovascular Disease.
Sleep Apnea and Cardiovascular Disease. An American Heart Association/American College of Cardiology Foundation Scientific Statement
Sleep-related breathing disorders are highly prevalent in patients with established cardiovascular disease. Obstructive sleep apnea (OSA) affects an estimated 15 million adult Americans and is present in a large proportion of patients with hypertension and in those with other cardiovascular disorders, including coronary artery disease, stroke, and atrial fibrillation.1–14 In contrast, central sleep apnea (CSA) occurs mainly in patients with heart failure.15–19 The purpose of this Scientific Statement is to describe the types and prevalence of sleep apnea and its relevance to individuals who either are at
risk for or already have established cardiovascular disease.
Special emphasis is given to recognizing the patient with cardiovascular disease who has coexisting sleep apnea, to understanding the mechanisms by which sleep apnea may contribute to the progression of the cardiovascular condition, and to identifying strategies for treatment./.../
Sleep-related breathing disorders are highly prevalent in patients with established cardiovascular disease. Obstructive sleep apnea (OSA) affects an estimated 15 million adult Americans and is present in a large proportion of patients with hypertension and in those with other cardiovascular disorders, including coronary artery disease, stroke, and atrial fibrillation.1–14 In contrast, central sleep apnea (CSA) occurs mainly in patients with heart failure.15–19 The purpose of this Scientific Statement is to describe the types and prevalence of sleep apnea and its relevance to individuals who either are at
risk for or already have established cardiovascular disease.
Special emphasis is given to recognizing the patient with cardiovascular disease who has coexisting sleep apnea, to understanding the mechanisms by which sleep apnea may contribute to the progression of the cardiovascular condition, and to identifying strategies for treatment./.../
Monday, July 28, 2008
Don't quit on smokers: If at first they don't succeed... ... American Medical News
AMNews: Aug. 4, 2008. Don't quit on smokers: If at first they don't succeed... ... American Medical News: "Physicians and patients have been down this road before -- many times. The physician keeps bringing up the subject of smoking cessation. The patient tries to quit and fails, even though he or she knows that parting ways with those villainous cigarettes is long overdue. Still, the breakup is elusive.
And here the two sit again, confronting the question: Will the next attempt be successful, or is it time for the patient to surrender to the pull of nicotine once and for all?"/.../
www.ahrq.gov/path/tobacco.htm
And here the two sit again, confronting the question: Will the next attempt be successful, or is it time for the patient to surrender to the pull of nicotine once and for all?"/.../
www.ahrq.gov/path/tobacco.htm
Development Outreach: Business and Poverty: Opening markets to the poor
WorldBank: Development Outreach: "In recent years, business has played a significant role in alleviating poverty, especially in sectors such as telecommunications, information technology, and microfinance. Certain initiatives in these sectors, such as microfinance in urban Latin America and wireless telecommunication in Asia, have yielded impressive results, creating unrealistic benchmarks against which other corporate programs are being judged. Although businesses have made significant contributions in some sectors, in many others they have been unable to “move the needle” on poverty.1"/.../
Sunday, July 27, 2008
Managing Prediabetes
Recommended by Catherine Coleman ProCOR
Physician's First Watch: "Consensus Statement Issued for Managing Prediabetes
The American College of Endocrinology has issued its first guidelines for management of patients with prediabetes.
Among the recommendations:
Patients with prediabetes (fasting glucose: 100–125 mg/dL; or 2-hour post-glucose challenge: 140–199 mg/dL) should undergo annual glucose tolerance and microalbuminuria testing.
Fasting plasma glucose, hemoglobin A1c, and lipids should be checked every 6 months.
As first-line treatment, patients should reduce their weight by 5%–10%, exercise for 30 to 60 minutes 5 days a week, and follow a low-fat, high-fiber diet.
For high-risk patients (e.g., those with worsening glycemia or cardiovascular disease), metformin and acarbose may be considered.
Lipid targets are the same as for patients with diabetes (e.g., LDL: 100 mg/dL); statins are recommended.
Blood pressure targets are also the same as for diabetic patients (systolic BP: <130 mm Hg; diastolic: 80 mm Hg), and ACE inhibitors and angiotensin receptor blockers should be considered first-line agents.
LINK(S):
Prediabetes consensus statement (Free PDF)
Published in Physician's First Watch July 24, 2008"
Physician's First Watch: "Consensus Statement Issued for Managing Prediabetes
The American College of Endocrinology has issued its first guidelines for management of patients with prediabetes.
Among the recommendations:
Patients with prediabetes (fasting glucose: 100–125 mg/dL; or 2-hour post-glucose challenge: 140–199 mg/dL) should undergo annual glucose tolerance and microalbuminuria testing.
Fasting plasma glucose, hemoglobin A1c, and lipids should be checked every 6 months.
As first-line treatment, patients should reduce their weight by 5%–10%, exercise for 30 to 60 minutes 5 days a week, and follow a low-fat, high-fiber diet.
For high-risk patients (e.g., those with worsening glycemia or cardiovascular disease), metformin and acarbose may be considered.
Lipid targets are the same as for patients with diabetes (e.g., LDL: 100 mg/dL); statins are recommended.
Blood pressure targets are also the same as for diabetic patients (systolic BP: <130 mm Hg; diastolic: 80 mm Hg), and ACE inhibitors and angiotensin receptor blockers should be considered first-line agents.
LINK(S):
Prediabetes consensus statement (Free PDF)
Published in Physician's First Watch July 24, 2008"
GEECAB: CURITIBA NO CONGRESSO da SBC
Prezados AMICOR,
Estamos planejando um encontro do GEECAB (Grupo de Trabalho em Epidemiologia e Cardiologia Baseada em Evidências) da SBC, para o dia 06 de setembro próximo, na véspera da abertura do Congresso Nacional de Curitiba, para planejar um Seminário Nacional sobre Epidemiologia e Prevenção para o próximo ano.
Deverá ser no estilo do que realizamos em Gramado em 1997.
Eu e Dra. Glaucia M. Oliveira, Presidente do GT estamos interessados em saber quem tem planos de lá estar nesta data, ou está interessado neste Seminário. Mesmo quem não puder ir, poderá opinar ou dar sugestões. Pretendemos manter todos informados.
Estamos planejando um encontro do GEECAB (Grupo de Trabalho em Epidemiologia e Cardiologia Baseada em Evidências) da SBC, para o dia 06 de setembro próximo, na véspera da abertura do Congresso Nacional de Curitiba, para planejar um Seminário Nacional sobre Epidemiologia e Prevenção para o próximo ano.
Deverá ser no estilo do que realizamos em Gramado em 1997.
Eu e Dra. Glaucia M. Oliveira, Presidente do GT estamos interessados em saber quem tem planos de lá estar nesta data, ou está interessado neste Seminário. Mesmo quem não puder ir, poderá opinar ou dar sugestões. Pretendemos manter todos informados.
Saturday, July 26, 2008
Bill Gates & Bloomberg: Tobacco Control
Hola, amigos:
En el enlace que aparece abajo verán 8 segmentos de video en Youtube con la conferencia de prensa donde se anunció en NY el donativo de fondos adicionales para el control del tabaco. ....................................................
http://www.youtube.com/watch?
Saludos / Greetings,
Beatriz
Beatriz Marcet Champagne, PhD
InterAmerican Heart Foundation
www.interamericanheart.org
Dra. María Paz Corvalán
MEDEF-Chile http://www.medef.com.ar
Globalink NIMI-Español
http://newses.globalink.org/
http://join.globalink.org/
INWAT http://www.inwat.org/
MEDEF-Chile http://www.medef.com.ar
Globalink NIMI-Español
http://newses.globalink.org/
http://join.globalink.org/
INWAT http://www.inwat.org/
Friday, July 25, 2008
How have Global Health Initiatives impacted on health equity?
How have Global Health Initiatives impacted on health equity? Johanna Hanefeld Health Policy Unit, London School of Hygiene and Tropical MedicinePromotion & Education, Vol. 15, No. 1, 19-23 (2008) PDF online at: http://ped.sagepub.com/cgi/reprint/15/1/19 Website: http://ped.sagepub.com/cgi/content/refs/15/1/19 “……..This review examines the impact of Global Health Initiatives (GHIs) on health equity, focusing on low- and middle-income countries.
Thursday, July 24, 2008
Global Atlas of the Health Workforce
Global Atlas of the Health Workforce
There is a growing need for high quality information on human resources in health systems to inform decision making for policies and programmes at the national and international levels. The WHO Department of Human Resources for Health has been collecting and compiling cross-nationally comparable data on health workers in all WHO Member States. The data available in the Global Atlas of the Health Workforce is the main outcome of this effort. Estimates of the stock (absolute numbers) and density (per 1000 population) of the health workforce are available here for 193 Member States. National-level data refer to the active health workforce, that is, all persons currently participating in the health labour market. Counting health workers poses challenges, including how to define them. The World Health Report 2006 defines health workers as "all people engaged in actions whose primary intent is to enhance health." Various permutations and combinations of what constitutes the health workforce potentially exist depending of each country's situation and the means of measurement. The information presented here reflects a framework for harmonizing the boundaries and constituency of the health workforce across contexts. Two sets of data are contained in the Global Atlas: a main (aggregated) set and a disaggregated set. The aggregated dataset includes estimates of the stock and density of health workers for up to 9 occupational categories. This includes: (i) physicians; (ii) nursing and midwifery personnel; (iii) dentistry personnel; (iv) pharmaceutical personnel; (v) laboratory health workers; (vi) environmental and public health workers; (vii) community and traditional health workers; (viii) other health service providers; and (ix) health management and support workers, that is, those who do not provide services directly but are critical to the performance of health systems. In the disaggregated dataset, estimates of the stock of health workers are available for some countries for up to 18 occupational categories, reflecting greater distinction of some categories of workers according to assumed differences in skill level and skill specialization. More information on the framework for categorizing health workers can be found in the definition notes. /.../
There is a growing need for high quality information on human resources in health systems to inform decision making for policies and programmes at the national and international levels. The WHO Department of Human Resources for Health has been collecting and compiling cross-nationally comparable data on health workers in all WHO Member States. The data available in the Global Atlas of the Health Workforce is the main outcome of this effort. Estimates of the stock (absolute numbers) and density (per 1000 population) of the health workforce are available here for 193 Member States. National-level data refer to the active health workforce, that is, all persons currently participating in the health labour market. Counting health workers poses challenges, including how to define them. The World Health Report 2006 defines health workers as "all people engaged in actions whose primary intent is to enhance health." Various permutations and combinations of what constitutes the health workforce potentially exist depending of each country's situation and the means of measurement. The information presented here reflects a framework for harmonizing the boundaries and constituency of the health workforce across contexts. Two sets of data are contained in the Global Atlas: a main (aggregated) set and a disaggregated set. The aggregated dataset includes estimates of the stock and density of health workers for up to 9 occupational categories. This includes: (i) physicians; (ii) nursing and midwifery personnel; (iii) dentistry personnel; (iv) pharmaceutical personnel; (v) laboratory health workers; (vi) environmental and public health workers; (vii) community and traditional health workers; (viii) other health service providers; and (ix) health management and support workers, that is, those who do not provide services directly but are critical to the performance of health systems. In the disaggregated dataset, estimates of the stock of health workers are available for some countries for up to 18 occupational categories, reflecting greater distinction of some categories of workers according to assumed differences in skill level and skill specialization. More information on the framework for categorizing health workers can be found in the definition notes. /.../
Tuesday, July 22, 2008
Bernard Lown New Book
Message received from:
Coleman, Catherine
Hello friends,One of the first articles about Dr Lown and his new book appeared on Sunday,here is the link.
http://www.boston.com/news/local/articles/2008/07/20/a_prescription_for_good_deeds/?page=full
For info about readings etc visit www.bernardlown.org.
The book is a GREAT read! It's exciting and inspiring and fascinating. Availablefrom Amazon.
Catherine
Catherine Coleman
Editor in Chief ProCOR
Lown Cardiovascular Research Foundation
21 Longwood Avenue, Brookline, MA 02446 USA
www.procor.orgccoleman5@partners.org
Coleman, Catherine
Hello friends,One of the first articles about Dr Lown and his new book appeared on Sunday,here is the link.
http://www.boston.com/news/local/articles/2008/07/20/a_prescription_for_good_deeds/?page=full
For info about readings etc visit www.bernardlown.org.
The book is a GREAT read! It's exciting and inspiring and fascinating. Availablefrom Amazon.
Catherine
Catherine Coleman
Editor in Chief ProCOR
Lown Cardiovascular Research Foundation
21 Longwood Avenue, Brookline, MA 02446 USA
www.procor.orgccoleman5@partners.org
Monday, July 21, 2008
warnings for fluoroquinolones ... American Medical News
AMNews: July 28, 2008. FDA requires black-box warnings for fluoroquinolones ... American Medical News: "FDA requires black-box warnings for fluoroquinolones
Associated risk of tendon injuries is higher among older patients, those on steroids and transplant recipients.
By Susan J. Landers, AMNews staff. July 28, 2008.
Washington -- The Food and Drug Administration has notified the makers of fluoroquinolone antimicrobials that they need to place boxed warnings on the labels of seven drugs in this class because they pose a risk for tendinitis and tendon rupture.
The FDA said a medication guide to inform patients also is necessary."/.../
Associated risk of tendon injuries is higher among older patients, those on steroids and transplant recipients.
By Susan J. Landers, AMNews staff. July 28, 2008.
Washington -- The Food and Drug Administration has notified the makers of fluoroquinolone antimicrobials that they need to place boxed warnings on the labels of seven drugs in this class because they pose a risk for tendinitis and tendon rupture.
The FDA said a medication guide to inform patients also is necessary."/.../
Subscribe to:
Posts (Atom)